Home › Compound Library › Itraconazole (Sporanox)

Itraconazole (Sporanox)

Antibioticprescriptionoral · inferred

Triazole antifungal with activity against Aspergillus, dermatophytes, Candida, histoplasmosis, blastomycosis, coccidioidomycosis, and sporotrichosis. Capsules: 100-200 mg BID with food and acidic beverage (cola) for absorption; oral solution (cyclodextrin-based): better F on empty stomach; SUBA-itraconazole improved F. Nonlinear PK at steady state (t1/2 extends from ~21h single-dose to 30-40h at steady state). Capsule oral F ~55%. Potent CYP3A4 inhibitor (major interaction liability). BOXED WARNING: negative inotrope/CHF risk. TDM recommended (trough >0.5-1 mg/L).

Projected serum levels — 200 mg, twice daily

Itraconazole (Sporanox)
Itraconazole (Sporanox) modeled serum levels, 200 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 3 days. 0 5 10 15 20 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 3
Itraconazole (Sporanox) modeled serum levels with a loading dose of 600 mg, then 200 mg twice daily The first dose is larger so levels approach steady state faster. 0 5 10 15 20 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 200 mg twice daily (oral).

Loading schedule: 600 mg on day 1, then 200 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~3 days: peak ≈ 12.7 mg, trough ≈ 9.7 mg body load. Population-based estimate over 15 days for a 200 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antibiotic
Route modeled
Oral
Model confidence
inferred
Half-life
21 h
Common dose
200 mg
Suggested maximum
400 mg/day
Reference dose range
100–400 mg (single dose)
Suggested cadence
twice daily
Validated against
200 mg oral — Cmax 0.28 mg/L at 4 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Itraconazole (Sporanox) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Itraconazole (Sporanox) AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Itraconazole (Sporanox) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Itraconazole (Sporanox) AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Itraconazole (Sporanox) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Itraconazole (Sporanox) AUC by ~5.00x

  • contraindicated
    Diltiazem + Itraconazole (Sporanox) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Itraconazole (Sporanox) AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Itraconazole (Sporanox) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Itraconazole (Sporanox) AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Itraconazole (Sporanox) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Itraconazole (Sporanox) AUC by ~10.00x

Serum checks 420 modeled interaction pairings for itraconazole (sporanox) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers Barone JA et al. · Antimicrobial Agents and Chemotherapy, 1993 DOI

    Seminal PK study establishing capsule food-enhanced absorption, nonlinear accumulation, and steady-state exposure for itraconazole.

  2. Itraconazole: an updated review of its pharmacological properties and therapeutic use in the management of opportunistic fungal infections Grant SM, Clissold SP · Drugs, 1989 DOI

    Classical therapeutic review summarizing itraconazole PK, spectrum, clinical efficacy, and drug-interaction profile; long-cited PK reference.

2 published studies referenced in the app, each with a plain-language summary.